Performance of SD Bioline Syphilis 3.0 for the Diagnosis of Syphilis a UPFR in Immunology of CHU-JRA

Arinomenjanahary Rakotoarisoa1*, Herinjaka Andriamandimbisoa1, Toky Randriamahazo2, Jaonoharimandimby Andrianavalona2, Davidra Rajaonatahiana3 and Andry Rasamindrakotroka3

1Internal Medical Biology, 2Chief Work in Medical Biology, 3Department of Immunology, CHU – JRA, Antananarivo, Madagascar
*Corresponding author

ABSTRACT

Serology is considered the pillar of the syphilis diagnosis. The limitations of traditional serological methods, the advent and availability of new immunochromatographic tests have led to the widespread application of rapid procedures as syphilis screening tools. However, these tests are not widely evaluated. This study was designed to evaluate the performance of a rapid diagnostic test for syphilis known as SD BIOLINE Syphilis 3.0. We carried out a prospective study at the Paraclinical Training and Research Unit in Immunology at the University Hospital Center in Antananarivo from March to May 2016 (3 months). We used SD BIOLINE Syphilis 3.0 to test a sample. Test performance was evaluated using Treponema pallidum Hemagglutination Assay (TPHA) and Rapid Plasma Reagin (RPR) as the reference standard, sensitivity, specificity, positive and negative predictive values were calculated. We have thirty-two reactive samples and eight non-reactive samples. The sensitivity, specificity, and positive and negative predictive values of SD BIOLINE Syphilis 3.0 were 100%. Keeping in view the high sensitivity and specificity of SD BIOLINE Syphilis 3.0 we conclude that the test can be used as a tool for the syphilis rapid diagnosis and as an alternative to TPHA for the detection of antibodies to Treponema pallidum.

Keywords: Non-treponemal tests, Fast, Serodiagnosis, Syphilis, Treponemal tests.

Accepted: 14 June 2017
Available Online: 10 August 2017

Introduction

Syphilis is a sexually transmitted infection (STI) caused by the bacterium Treponema pallidum (T. pallidum), a disease that is becoming widespread. According to the WHO in 2012; 900000 women were infected by syphilis in the world. Furthermore, the inability of culture of the pathogenic microorganism in vitro and the limited availability of nucleic acid amplification techniques makes the diagnosis of this infection difficult [1]. Serology is therefore considered to be the pillar of the syphilis diagnosis. The serological diagnosis of syphilis is based with detection of the two types antibodies directed against the cardiolipin antigen and treponemal-specific antibodies [2, 3]. A major limitation of diagnosis is encountered with the use of tests based on antiphospholipid antibodies (non-treponemal test) giving false positive results [4, 5, 6]. It is therefore recommended to use non-treponemal tests...
such as VDRL and Rapid Plasma Reinforce (RPR) for screening tests and then confirmed by more specific treponemal tests such as *T. pallidum* hemagglutination Assay (TPHA) Fluorescent treponemal antibodies [7, 8, and 9]. False negative reactions due to the zone phenomenon are also seen with non-treponemal tests [10]. Moreover, the tests lack sensitivity in the latent stage of latent infection [11]. A major disadvantage of the laboratory procedures currently used for syphilis serodiagnosis, which require various materials (refrigeration, water bath, centrifuge, rotators, etc.); strict quality control measures and qualified individuals to perform the tests, as well as trained health professionals to read and interpret the results. In the stress parameters, laboratory infrastructure and facilities for the diagnosis of syphilis may not be widely available, and the delay in obtaining samples tested by reference laboratories may prevent timely initiation of treatment. This is reflected in the continued transmission of the disease to naïve or uninfected individuals. The current situation requires to need for rapid and reliable tests used for screening and confirmatory testing in all stages of syphilis. Rapid serological procedures offer a potential option with assured rapid availability of results generally <15 min and ease of use by healthcare professionals allowing on-site testing. The World Health Organization has established a diagnostic initiative for sexually transmitted diseases, the "ASSURED" criteria that define the characteristics of the rapid test ideal and a point of care test (Affordable, sensitive, specific, user- [12-14]. It is also available as an affordable, sensitive, specific, fast and robust device that is easy to use for free and available to those who need it. Several rapid *T. pallidum* recombinant antigens are now commercially available [15]. Despite the advantages that rapid tests offer over traditional laboratory methods for the diagnosis of syphilis, their diagnostic performance remains a concern and is still poorly documented. In this study, the authors evaluated the performance of SD BIOLINE Syphilis 3.0, a rapid immunochromatographic test that qualitatively detects antibodies against *T. pallidum*.

**Materials and Methods**

This prospective study was conducted at the Paraclinical Unit of Training and Research in Immunology at the University Hospital Center of Antananarivo, from March to May 2016 (3 months). This study was duly approved by the Head of Unit. Samples of consecutive blood samples received at the serology laboratory with syphilis screening were included in the analysis.

All reactive RPR sample were diluted serially to determine the antibody titer. Three different staff performed the analysis: the first technician who did not have access to the results of the screening test performed the TPHA according to the manufacturer's instructions in the kit. A second performed the TPHA and then the third laboratory technician performed the test on SD BIOLINE Syphilis 3.0 per the manufacturer's guidelines.

The results of the RPR, TPHA and SD BIOLINE Syphilis 3.0 assays were entered the Microsoft Excel sheet and discordant results by TPHA and SD BIOLINE Syphilis 3.0 were retested by both procedures before finally being recorded as positive or negative.

Calculation and estimation of the positive, negative predictive values of SD BIOLINE Syphilis 3.0 sensitivity and specificity were performed by comparing its performance with TPHA (reference technique). Sensitivity was calculated as true positive / (true positive + false negative) × 100; Specificity as true negatives / (true negatives + false positives) \times 100;
Results and Discussion

We worked on 40 samples including 8 RPR negative and 32 RPR reactive samples, TPHA positive, and reactive with SD BIOLINE Syphilis 3.0. All non-reactive RPR sample (n = 8) were negative both by TPHA and the rapid test. The performance of SD BIOLINE Syphilis 3.0 and RPR against TPHA is presented in table 1.

We report the sensitivity and specificity of 100% values for SD BIOLINE Syphilis 3.0, relative to TPHA as the reference standard. A study in Tanzania found that the test was 79% sensitive and 96% specific [16]. In another study conducted in China, reported sensitivity and specificity values were 95.5% and 97.9%, respectively [17].

Thus, bearing in mind the high sensitivity and specificity of SD BIOLINE syphilis 3.0, we conclude that the assay can be used both as a screening test and as an alternative to TPHA for the detection of antibodies directed against T. pallidum. The low sensitivity of immunochromatographic tests has been reported in previous studies, and the reason given was mainly the low levels of antibodies found in sera from patients with primary early syphilis [18].

SD BIOLINE Syphilis 3.0 is a quick one-step test that is easy to perform, read and interpret. In addition to serum samples, the test is also compatible with whole blood and plasma. Therefore, the test does not require any pretreatment of specimens or any laboratory or qualified technical personnel to perform the test procedure. This makes the test an ideal on-site option in screening in health facilities without laboratory facilities.

Furthermore, since the T. pallidum-specific antibody test does not give a false positive and the test can also be used as an alternative to TPHA to confirm reactivity in non-treponemal tests. The rapid availability of results with the use of this test would also ensure rapid treatment of reactive patients in their first visit to health care services.

<table>
<thead>
<tr>
<th>Résults</th>
<th>RPR</th>
<th>TPHA</th>
<th>SB BIOLINE Syphilis3.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positif</td>
<td>32</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Négatif</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Sensibilité</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Spécificité</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

TPHA*: Treponema pallidum hemagglutination assay;
RPR**: Réagine plasmatique rapide
The test, however, faces some shortcomings. An important constraint for its application as a screening tool is that the treponemal-specific antibodies detected by the test are conserved for years and thus cannot distinguish past treated infections from recent or active infections [20]. This implies that many previously infected and treated people would also be captured by SD BIOLINE syphilis 3.0, especially in high-prevalence settings, leading to unnecessary treatment of patients.

The test may also give a positive result in various non-venereal treponematoses such as yaws and pinta [21]. However, some researchers argue that false-positive results are preferable to false negatives [22]. Although a false negative result, a syphilitic patient may not be treated and transmit the infection to others; A false positive serology would at least be repeated with alternative methods before a definitive diagnosis is made. In this context, we propose to adopt an inverse algorithm whereby a non-treponemal test such as VDRL or RPR could be used to document the active disease in patients with a reactive test at the point of care and then confirm it by the test fast. However, these tests are still under evaluation and not available for routine use.

Our study is very important from a public health perspective and based on our findings, we recommend the use of rapid care point procedures such as SD BIOLINE Syphilis 3.0. Screening tests as primary for the serodiagnosis of syphilis, where laboratory facilities are not available and tests to confirm the non-treponemal reactivity where TPHA cannot be done. The study was carried out in the UPFR in Immunology of the CHU-JRA. The laboratory receives many samples of diverse people from inpatients and outpatients, from various departments of hospitals.

This study has some limitations. First, the number of sample in the panel used to evaluate the kit is low. In addition, our laboratory study and evaluation was not given in the field or clinical conditions for which the test is primarily intended. In addition, the test kit was evaluated using exclusively serum samples and its performance characteristics with whole blood and plasma specimens are not determined. In addition, we don’t have clinical information on the cases from which the reactive sample was obtained and therefore the performance of the test according to the stage of syphilis could not be assessed.

In conclusion, we strongly recommend the use of SD BIOLINE Syphilis 3.0 for the diagnosis of rapid on-site syphilis. Further field studies are needed before the test can be systematically implemented as a screening test.

References


Rusnak JM, Butzin C, McGlasson D, Blatt


West B, Walraven G, Morison L, Brouwers J, Bailey R. Performance of the rapid plasma reagin and the rapid syphilis screening tests in the diagnosis of


How to cite this article:


doi: [https://doi.org/10.20546/ijcmas.2017.608.099](https://doi.org/10.20546/ijcmas.2017.608.099)